

**This communication should be viewed by:**

Primary Care Providers  
Behavioral Health Providers  
Clinical staff

## Pharmaceutical Policies Updates Effective December 1, 2023

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at [mvphealthcare.com](http://mvphealthcare.com) and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective December 1, 2023 and will be available for viewing on or before November 1, 2023. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Entyvio	Reviewed/No Changes
Risankizumab (Skyrizi)	Updated
Ustekinumab (Stelara)	Updated
Proton Pump Inhibitor Therapy	Updated
Hemophilia Factor	Reviewed/No Changes
Colony Stimulating Factor	Updated
Erythropoiesis Stimulating Agents	Reviewed/No Changes
Hereditary Angioedema	Reviewed/No Changes
Gaucher Disease Type 1 Treatment	Reviewed/No Changes
Select Chelating Agents	Updated
Enteral Therapy VT	Reviewed/No Changes
Irritable Bowel Syndrome	Updated
Biosimilars, Select Medical	Reviewed/No Changes
Intestinal Antibiotics	Reviewed/No Changes
Mulpleta/Doptelet	Reviewed/No Changes
Dojolvi	Reviewed/No Changes
Ozanimod (Zeposia)	Reviewed/No Changes
Etancercept (Enbrel)	Reviewed/No Changes
Tofacitinib (Xeljanz)	Reviewed/No Changes
Guzelkumab (Tremfya)	Reviewed/No Changes

To view all communications, visit [mvphealthcare.com/FastFax](http://mvphealthcare.com/FastFax)

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



Tepezza	Updated
Adakveo	Updated
Upadacitinib (Rinvoq)	Updated
Secukinumab (Cosentyx)	Updated
Adalimumab (Humira)	Updated
Apremilast (Otezla)	Updated
Soliris	New
Ultomiris	New
Hemophilia Gene Therapy <i>*Effective October 1, 2023*</i>	New
Vascular Endothelial Growth Factor (VEGF) Inhibitor <i>*Effective November 1, 2023*</i>	New
Weight Loss Medications <i>*Effective January 1, 2024*</i>	New

### It's Time to Recertify Your Patients!\*

The Families First Coronavirus Response Act has expired. To learn how MVP can help your patients continue their coverage, visit [mvphealthcare.com/recertification](https://mvphealthcare.com/recertification).

\*Applies to Members enrolled in Medicaid, Child Health Plus (CHP), Health and Recovery Plan (HARP), and the Essential Plan (EP).

To view all faxed messages, visit [mvphealthcare.com/FastFax](https://mvphealthcare.com/FastFax).

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

